{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:11:27Z","timestamp":1795104687173,"version":"4.10.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"7970","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,7,20]]},"DOI":"10.1038\/s41586-023-06234-x","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T12:05:10Z","timestamp":1687349110000},"page":"624-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Y chromosome loss in cancer drives growth by evasion of adaptive immunity"],"prefix":"10.1038","volume":"619","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5402-5540","authenticated-orcid":false,"given":"Hany A.","family":"Abdel-Hafiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-5621","authenticated-orcid":false,"given":"Johanna M.","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-2130","authenticated-orcid":false,"given":"Timothy D.","family":"Gauntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-927X","authenticated-orcid":false,"given":"Zihai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8708-8206","authenticated-orcid":false,"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"6234_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jnci\/djz232","volume":"112","author":"A Caceres","year":"2020","unstructured":"Caceres, A., Jene, A., Esko, T., Perez-Jurado, L. A. & Gonzalez, J. R. Extreme downregulation of chromosome Y and cancer risk in men. J. Natl Cancer Inst. 112, 913\u2013920 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"6234_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1008-682X.150842","volume":"17","author":"T Kido","year":"2015","unstructured":"Kido, T. & Lau, Y. F. Roles of the Y chromosome genes in human cancers. Asian J. Androl. 17, 373\u2013380 (2015).","journal-title":"Asian J. Androl."},{"key":"6234_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/jnci\/djz236","volume":"112","author":"DW Brown","year":"2020","unstructured":"Brown, D. W. & Machiela, M. J. Why Y? Downregulation of chromosome Y genes potentially contributes to elevated cancer risk. J. Natl Cancer Inst. 112, 871\u2013872 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"6234_CR4","first-page":"319","volume":"26","author":"AD Panani","year":"2006","unstructured":"Panani, A. D. & Roussos, C. Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma. Anticancer Res. 26, 319\u2013323 (2006).","journal-title":"Anticancer Res."},{"key":"6234_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0165-4608(95)00030-S","volume":"82","author":"G Sauter","year":"1995","unstructured":"Sauter, G. et al. Y chromosome loss detected by FISH in bladder cancer. Cancer Genet. Cytogenet. 82, 163\u2013169 (1995).","journal-title":"Cancer Genet. Cytogenet."},{"key":"6234_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0165-4608(90)90242-3","volume":"50","author":"I Powell","year":"1990","unstructured":"Powell, I., Tyrkus, M. & Kleer, E. Apparent correlation of sex chromosome loss and disease course in urothelial cancer. Cancer Genet. Cytogenet. 50, 97\u2013101 (1990).","journal-title":"Cancer Genet. Cytogenet."},{"key":"6234_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ejhg.2017.128","volume":"25","author":"AA Maan","year":"2017","unstructured":"Maan, A. A. et al. The Y chromosome: a blueprint for men\u2019s health? Eur. J. Hum. Genet. 25, 1181\u20131188 (2017).","journal-title":"Eur. J. Hum. Genet."},{"key":"6234_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ymthe.2017.05.021","volume":"25","author":"F Adikusuma","year":"2017","unstructured":"Adikusuma, F., Williams, N., Grutzner, F., Hughes, J. & Thomas, P. Targeted deletion of an entire chromosome using CRISPR\/Cas9. Mol. Ther. 25, 1736\u20131738 (2017).","journal-title":"Mol. Ther."},{"key":"6234_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.abn3100","volume":"377","author":"S Sano","year":"2022","unstructured":"Sano, S. et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science 377, 292\u2013297 (2022).","journal-title":"Science"},{"key":"6234_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/ng.2966","volume":"46","author":"LA Forsberg","year":"2014","unstructured":"Forsberg, L. A. et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet. 46, 624\u2013628 (2014).","journal-title":"Nat. Genet."},{"key":"6234_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1034>3.0.CO;2-O","volume":"29","author":"I Fadl-Elmula","year":"2000","unstructured":"Fadl-Elmula, I. et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 29, 256\u2013265 (2000).","journal-title":"Genes Chromosomes Cancer"},{"key":"6234_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000052252","volume":"33","author":"G Sauter","year":"1998","unstructured":"Sauter, G., Moch, H., Mihatsch, M. J. & Gasser, T. C. Molecular cytogenetics of bladder cancer progression. Eur. Urol. 33, 9\u201310 (1998).","journal-title":"Eur. Urol."},{"key":"6234_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0165-4608(87)90028-8","volume":"29","author":"W Smeets","year":"1987","unstructured":"Smeets, W., Pauwels, R., Laarakkers, L., Debruyne, F. & Geraedts, J. Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet. Cytogenet. 29, 29\u201341 (1987).","journal-title":"Cancer Genet. Cytogenet."},{"key":"6234_CR14","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1007\/BF00942046","volume":"25","author":"G Sauter","year":"1997","unstructured":"Sauter, G. et al. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol. Res. 25, S37\u2013S43 (1997).","journal-title":"Urol. Res."},{"key":"6234_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0046-8177(99)90305-2","volume":"30","author":"M Neuhaus","year":"1999","unstructured":"Neuhaus, M. et al. Polysomies but not Y chromosome losses have prognostic significance in pTa\/pT1 urinary bladder cancer. Hum. Pathol. 30, 81\u201386 (1999).","journal-title":"Hum. Pathol."},{"key":"6234_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin.\u00a071, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"6234_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(SICI)1098-2388(199709\/10)13:5<291::AID-SSU2>3.0.CO;2-8","volume":"13","author":"SL Johansson","year":"1997","unstructured":"Johansson, S. L. & Cohen, S. M. Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol. 13, 291\u2013298 (1997).","journal-title":"Semin. Surg. Oncol."},{"key":"6234_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1126\/science.1262092","volume":"347","author":"JP Dumanski","year":"2015","unstructured":"Dumanski, J. P. et al. Smoking is associated with mosaic loss of chromosome Y. Science 347, 81\u201383 (2015).","journal-title":"Science"},{"key":"6234_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/CCO.0000000000000445","volume":"30","author":"W Tabayoyong","year":"2018","unstructured":"Tabayoyong, W. & Gao, J. The emerging role of immunotherapy in advanced urothelial cancers. Curr. Opin. Oncol. 30, 172\u2013180 (2018).","journal-title":"Curr. Opin. Oncol."},{"key":"6234_CR20","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00345-018-2332-5","volume":"36","author":"M Rouanne","year":"2018","unstructured":"Rouanne, M. et al. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J. Urol. 36, 1727\u20131740 (2018).","journal-title":"World J. Urol."},{"key":"6234_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1152\/physiolgenomics.00074.2015","volume":"47","author":"JW Prokop","year":"2015","unstructured":"Prokop, J. W. & Deschepper, C. F. Chromosome Y genetic variants: impact in animal models and on human disease. Physiol. Genomics 47, 525\u2013537 (2015).","journal-title":"Physiol. Genomics"},{"key":"6234_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e525 (2017).","journal-title":"Cell"},{"key":"6234_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog, S. V. et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 12, 2301 (2021).","journal-title":"Nat. Commun."},{"key":"6234_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12859-020-03768-z","volume":"21","author":"JR Gonzalez","year":"2020","unstructured":"Gonzalez, J. R. et al. MADloy: robust detection of mosaic loss of chromosome Y from genotype-array-intensity data. BMC Bioinformatics 21, 533 (2020).","journal-title":"BMC Bioinformatics"},{"key":"6234_CR25","first-page":"1017","volume":"62","author":"IC Summerhayes","year":"1979","unstructured":"Summerhayes, I. C. & Franks, L. M. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J. Natl Cancer Inst. 62, 1017\u20131023 (1979).","journal-title":"J. Natl Cancer Inst."},{"key":"6234_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/j.1464-410X.2009.08577.x","volume":"104","author":"E Chan","year":"2009","unstructured":"Chan, E., Patel, A., Heston, W. & Larchian, W. Mouse orthotopic models for bladder cancer research. BJU Int. 104, 1286\u20131291 (2009).","journal-title":"BJU Int."},{"key":"6234_CR27","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.14440\/bladder.2016.73","volume":"3","author":"S White-Gilbertson","year":"2016","unstructured":"White-Gilbertson, S., Davis, M., Voelkel-Johnson, C. & Kasman, L. M. Sex differences in the MB49 syngeneic, murine model of bladder cancer. Bladder 3, e22 (2016).","journal-title":"Bladder"},{"key":"6234_CR28","doi-asserted-by":"publisher","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu, M. M. et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5, eaav2437 (2019).","journal-title":"Sci. Adv."},{"key":"6234_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/1097-0142(195209)5:5<979::AID-CNCR2820050514>3.0.CO;2-J","volume":"5","author":"K Sugiura","year":"1952","unstructured":"Sugiura, K. & Stock, C. C. The effect of 2,4,6-triethylenimino-s-triazine on the growth of a variety of mouse and rat tumors. Cancer 5, 979\u2013991 (1952).","journal-title":"Cancer"},{"key":"6234_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25103-7","volume":"12","author":"KH Gouin 3rd","year":"2021","unstructured":"Gouin, K. H. 3rd et al. An N-cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nat. Commun. 12, 4906 (2021).","journal-title":"Nat. Commun."},{"key":"6234_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2019","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","journal-title":"Nat. Biotechnol."},{"key":"6234_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"6234_CR33","doi-asserted-by":"publisher","first-page":"eabq2630","DOI":"10.1126\/sciimmunol.abq2630","volume":"7","author":"H Kwon","year":"2022","unstructured":"Kwon, H. et al. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci. Immunol. 7, eabq2630 (2022).","journal-title":"Sci. Immunol."},{"key":"6234_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"6234_CR35","doi-asserted-by":"publisher","first-page":"e153768","DOI":"10.1172\/jci.insight.153768","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis. JCI Insight 7, e153768 (2022).","journal-title":"JCI Insight"},{"key":"6234_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3109\/00313021003767298","volume":"42","author":"S Minner","year":"2010","unstructured":"Minner, S. et al. Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology 42, 356\u2013359 (2010).","journal-title":"Pathology"},{"key":"6234_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cancergen.2012.02.002","volume":"205","author":"VT Fabris","year":"2012","unstructured":"Fabris, V. T. et al. Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-I. Cancer Genet. 205, 168\u2013176 (2012).","journal-title":"Cancer Genet."},{"key":"6234_CR38","doi-asserted-by":"publisher","first-page":"eaai8312","DOI":"10.1126\/scitranslmed.aai8312","volume":"9","author":"LD Ler","year":"2017","unstructured":"Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci. Transl. Med. 9, eaai8312 (2017).","journal-title":"Sci. Transl. Med."},{"key":"6234_CR39","doi-asserted-by":"publisher","first-page":"18302","DOI":"10.1074\/jbc.M114.555052","volume":"289","author":"LJ Walport","year":"2014","unstructured":"Walport, L. J. et al. Human UTY(KDM6C) is a male-specific N-methyl lysyl demethylase. J. Biol. Chem. 289, 18302\u201318313 (2014).","journal-title":"J. Biol. Chem."},{"key":"6234_CR40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/0008-5472.CAN-15-0906","volume":"76","author":"N Li","year":"2016","unstructured":"Li, N. et al. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Res. 76, 831\u2013843 (2016).","journal-title":"Cancer Res."},{"key":"6234_CR41","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6234_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"6234_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-019-1765-3","volume":"575","author":"DJ Thompson","year":"2019","unstructured":"Thompson, D. J. et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature 575, 652\u2013657 (2019).","journal-title":"Nature"},{"key":"6234_CR44","first-page":"4286","volume":"52","author":"EC Lattime","year":"1992","unstructured":"Lattime, E. C., Gomella, L. G. & McCue, P. A. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res. 52, 4286\u20134290 (1992).","journal-title":"Cancer Res."},{"key":"6234_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","volume":"3","author":"MM Tu","year":"2020","unstructured":"Tu, M. M. et al. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun. Biol. 3, 720 (2020).","journal-title":"Commun. Biol."},{"key":"6234_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-021-01222-y","volume":"15","author":"NJ Song","year":"2022","unstructured":"Song, N. J. et al. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J. Hematol. Oncol. 15, 5 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"6234_CR47","doi-asserted-by":"publisher","first-page":"16718","DOI":"10.18632\/oncotarget.24676","volume":"9","author":"CS Richmond","year":"2018","unstructured":"Richmond, C. S. et al. Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. Oncotarget 9, 16718\u201316730 (2018).","journal-title":"Oncotarget"},{"key":"6234_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J.\u00a017, 10\u201312 (2011).","journal-title":"EMBnet J."},{"key":"6234_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"6234_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"6234_CR51","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"6234_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"6234_CR53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"6234_CR54","doi-asserted-by":"publisher","first-page":"890410","DOI":"10.3389\/fonc.2022.890410","volume":"12","author":"S Hernandez","year":"2022","unstructured":"Hernandez, S. et al. Challenges and opportunities for immunoprofiling using a spatial high-plex technology: the NanoString GeoMx((R)) digital spatial profiler. Front. Oncol. 12, 890410 (2022).","journal-title":"Front. Oncol."},{"key":"6234_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"6234_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"6234_CR57","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"6234_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"6234_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"6234_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"6234_CR61","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820\u2013832 (2021).","journal-title":"Nat. Med."},{"key":"6234_CR62","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447\u20133452 (2016).","journal-title":"J. Clin. Invest."},{"key":"6234_CR63","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Invest."},{"key":"6234_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"6234_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211.e110 (2019).","journal-title":"Immunity"},{"key":"6234_CR66","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"6234_CR67","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346\u20131358 (2020).","journal-title":"Nat. Immunol."},{"key":"6234_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen, M. & Andreatta, M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8, 33 (2016).","journal-title":"Genome Med."}],"updated-by":[{"DOI":"10.1038\/s41586-024-07104-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06234-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:07:20Z","timestamp":1706587640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06234-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":68,"journal-issue":{"issue":"7970","published-print":{"date-parts":[[2023,7,20]]}},"alternative-id":["6234"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06234-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742689670.793599852","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"1 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-024-07104-w","URL":"https:\/\/doi.org\/10.1038\/s41586-024-07104-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.L. reports personal consultation fees from Alphamab, HanchorBio, Henlius, Heat Biologic and Ikonisys outside the submitted work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}